Skip to main content
Premium Trial:

Request an Annual Quote

Six RNAi-Related Patent Applications Published by the US Patent Office: Dec 17, 2004

Premium

Title: Conjugates and Compositions for Cellular Delivery. Number: 20040249178. Filed: Feb. 13, 2004. Lead Inventor: Chandra Vargeese, Sirna Therapeutics.

The invention “features conjugates, degradable linkers, compositions, methods of synthesis, and applications thereof, including cholesterol, folate, galactose, galactosamine, N-acetyl galactosamine, PEG, phospholipid, peptide, and human serum albumin-derived conjugates of biologically active compounds including antibodies, antivirals, chemotherapeutics, peptides, proteins, hormones, nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymatic nucleic acids, DNAzymes, allozymes, antisense, dsRNA, siNA, siRNA, triplex oligonucleotides, 2,5-A chimeras, decoys, and aptamers,” the patent application’s abstract states.


Title: Poly-DNP siRNA. Number: 20040248841. Filed: March 15, 2004. Lead Inventor: Jui Wang, University at Buffalo.

According to the patent application’s abstract, “embodiments of the … invention provide methods ... for improving the stability or efficacy of the double stranded siRNAs by replacing either one or both of its native RNA strands with homologous RNase-resistant poly-DNP-RNA to form poly-DNP-siRNA. Additional embodiments include DNP-derivatized siRNAs with improved stability or efficacy compared to non-DNP-derivatized siRNAs.”


Title: RNAi Targeting of Viruses. Number: 20040248839. Filed: Feb. 5, 2004. Inventor: Timothy Kowalik, University of Massachusetts.

“The invention relates to methods and compositions that inhibit viral replication, e.g., CMV replication, within a host or host cell,” the patent application’s abstract states. “Methods and compositions of the invention utilize RNA interference to block the translation of mRNA into proteins which are important or essential to viral replication. The method and compositions can be used to study CMV infection in in vitro cell culture and to treat CMV infection in non-human primates and human subjects.”


Title: Use of a Double-Stranded Ribonucleic Acid for Treating an Infection with a Positive-Strand RNA Virus. Number: 20040248835. Filed: May 20, 2004. PCT Filed: Oct. 25, 2002. Lead Inventor: Anja Krebs, Alnylam Europe (Alnylam Pharmaceuticals).

“The invention concerns the use of a double-stranded ribonucleic acid to treat a [positive]-strand RNA virus infection, wherein one strand S1 of the dsRNA exhibits a region that is at least segmentally complementary to a segment of the translatable region of the virus genome,” the patent application’s abstract states.


Title: RNA Interference. Number: 20040248299. Filed: Dec. 22, 2003. Lead Inventor: Sumedha Jayasena, Amgen.

According to the patent application’s abstract, the invention “relates to RNA interference and methods for selecting interfering RNAs. The … invention also relates to modified interfering RNAs … [as well as] to methods of reducing the level of a specific mRNA in a cell, methods for reducing the level of a specific protein in a cell, and methods of regulating gene expression,” the abstract adds. “The … invention also relates to methods of screening libraries for an interfering RNA of interest and methods of screening libraries based on a gene function.”


Title: HIV Therapeutic. Number: 20040248296. Filed: March 20, 2003. Lead Inventor: Paul Beresford, Harvard Medical School.

The invention “provides siRNA methods and compositions for inhibiting HIV infection and/or replication, as well as systems for identifying effective siRNAs for inhibiting HIV and systems for studying HIV infective mechanisms,” the patent application’s abstract states. “The invention also provides methods and compositions for inhibiting infection, pathogenicity and/or replication of an infectious agent — for example, by using siRNAs to inhibit host cell gene expression.”

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.